Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04262388
Title A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

pancreatic ductal adenocarcinoma

lung non-small cell carcinoma

head and neck squamous cell carcinoma

Therapies

Durvalumab + Oleclumab

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.